Symbols

IOVA

Iovance·NASDAQ

--(--)

Market Open: --

--(--)

Pre-Market: --

Signals Analysis

Bullish signal 2

Bearish signal 1

Consensus Rating "Strong Buy"

Ample Liquidity

Revenue Below Expectations

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About IOVA

Iovance Biotherapeutics, Inc.

A late-stage biotech company that develops novel T cell-based cancer immunotherapies

Industry

Biological Technology

Established Date

09/17/2007

Listing Date

02/26/2015

Exchange

NASDAQ Stock Exchange

Full-time Employees

838

Fiscal Year Ends

12-31

Website

www.iovance.com

Security Type

Common stock

Office address

825 Industrial Road, Suite 400, San Carlos, California 94070

Business

Introduction

Iovance Biotherapeutics, Inc., is an emerging biotechnology company focused on the development and commercialization of cell therapy methods for cultured cells, using autologous tumor infiltrating lymphocytes (TILs) for the treatment of solid tumors such as metastatic melanoma. The company was founded in Nevada on September 17, 2007.

Earnings Call

Q1/2025

Estimate EPS-0.24

Actual EPS-0.36

Estimate Revenue81.53M

Actual Revenue49.30M

Iovance Biotherapeutics Q1 2025: Key Contradictions Unveiled on Manufacturing, Patient Growth, and European Revenue

May 19,2025 06:07·
Earnings Decrypt

Q2/2025

Estimate EPS-0.28

Actual EPS-0.33

Estimate Revenue67.14M

Actual Revenue60.00M

Contradictions in Focus: Analyzing Manufacturing Success, Proleukin Revenue, and Price Impacts in Q2 2025 Earnings Call

Aug 08,2025 03:29·
Earnings Decrypt

Company Financials

EPS

IOVA has released its 2025 Q3 earnings. EPS was reported at -0.25, versus the expected -0.26, beating expectations. The chart below visualizes how IOVA has performed over recent quarters, highlighting trends in earnings surprises.

Revenue & Expenses

IOVA has released its 2025 Q3 earnings report, with revenue of 67.45M, reflecting a YoY change of 15.20%, and net profit of -91.25M, showing a YoY change of -9.23%. The Sankey diagram below clearly presents IOVA's revenue sources and cost distribution.